News

The new project is expected to help the company in meeting the growing demand for its manufacturing services, which have quadrupled their revenues in the past four years.

The NX02-0018 trial is the second of two pivotal prospective double blind placebo-controlled US clinical trials being conducted to evaluate NX-1207 2.5mg for the treatment of benign prostatic

The results published in the latest issue of the New England Journal of Medicine (NEJM) show that letermovir in CMV-seropositive allogeneic human blood precursor cell recipients (bone marrow

The company said that its extensive C. diff patent estate now includes more than 25 US and international patents. Currently, the company is in preclinical development of SYN-004,

First study in the Phase III NSCLC programme, the PACIFIC trial is designed to evaluate progression free survival and overall survival of MEDI4736 compared to placebo in patients

This new patent addresses the composition and methods of a new compound described as a calcium-activated potassium channel opening agent for topical treatment of hair loss. DS Healthcare

In the suit, Acura alleges that a generic of Acura’s AVERSION oxycodone product, previously marketed by Pfizer under its brand name OXECTA, for which Ranbaxy is seeking approval

This is the latest innovative public-private partnership from the newly established Janssen Global Public Health group and a significant contribution to the wider efforts of Johnson & Johnson

Ganetespib is a next-generation inhibitor of the chaperone protein Hsp90, which is critical for the activation and stability of numerous proteins that drive cancer growth and proliferation. Ganetespib